Medicenna Therapeutics Corp. Research And Development Expense

Quick Answer

Medicenna Therapeutics Corp. reported Research And Development Expense of $9.30 million for the year ending 2023.

  • Medicenna Therapeutics Corp. showed a decrease of -36.8% in Research And Development Expense from 2022 to 2023.
  • This data is from Medicenna Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on June 27, 2023.
  • XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2020 to 2023), Medicenna Therapeutics Corp.'s Research And Development Expense has grown by 58.5%.
  • Historical annual values: Fiscal year 2023: $9.30 million | Fiscal year 2022: $14.72 million | Fiscal year 2021: $10.87 million | Fiscal year 2020: $5.87 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: